Table 1.
Clinical characteristics of patients with ICI‐associated primary adrenal insufficiency (n = 451) collected from VigiBase (last accessed October 2018)
| Characteristics | n (%) |
|---|---|
| Reporting region | |
| Americas | 211 (46.8) |
| Europe | 116 (25.7) |
| Australia | 8 (1.8) |
| Asia | 116 (25.7) |
| Reporters | |
| Health care professional | 364 (80.7) |
| Non–health care professional | 59 (13.1) |
| Unspecified | 28 (6.2) |
| Reporting year | |
| 2018 | 169 (37.5) |
| 2017 | 147 (32.6) |
| 2016 | 53 (11.7) |
| 2015 | 51 (11.3) |
| 2014 | 13 (2.9) |
| ≤2013 | 18 (4.0) |
| Sex | |
| Female | 162 (35.9) |
| Male | 262 (58.1) |
| Unspecified | 27 (6.0) |
| Age at onset (n = 369), median (range max), years | 66 (30–95) |
| Indication of ICI | |
| Skin cancer | 186 (41.2) |
| Lung cancer | 129 (28.6) |
| Renal cancer | 31 (6.9) |
| Gastrointestinal cancer | 6 (1.3) |
| Ovarian cancer | 2 (0.4) |
| Bladder cancer | 3 (0.7) |
| Pancreatic carcinoma | 2 (0.4) |
| Breast cancer | 3 (0.7) |
| Endometrial cancer | 3 (0.7) |
| Myeloma | 3 (0.7) |
| Glioblastoma | 2 (0.4) |
| Hepatocellular cancer | 1 (0.2) |
| Pleural cancer | 3 (0.7) |
| Vulvar cancer | 2 (0.4) |
| Prostate cancer | 1 (0.2) |
| Testis cancer | 1 (0.2) |
| Hodgkin's disease | 1 (0.2) |
| Neoplasm of unknown sites | 19 (4.2) |
| Data unspecified | 53 (11.7) |
Abbreviation: ICI, immune checkpoint inhibitor.